Currently, the treatment of CRS remains symptomatic (cytokine blockers and antibodies, e.g., IL-6 blockers, such as tocilizumab, sarilumab, and satralizumab; glucocorticoids; purifying blood to reduce cytokine levels in circulation) and is not aimed at reducing hyperactivation of immune cells, i.e., the primary cause of “cytokine storm”. Here, IL6 is linked to congenital rubella syndrome.